Latest Morning Briefing Stories
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
Parents Become Drug Developers to Save Their Children’s Lives
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: Life After ‘Roe’ Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Patients With Epilepsy Navigate Murky Unregulated CBD Industry
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
‘Free’ Screening? Know Your Rights to Get No-Cost Care
Even a decade in, the Affordable Care Act’s recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
Readers and Tweeters Weigh In on Medical Debt, the Obesity Epidemic, and Opioid Battles
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: The FDA Goes After Nicotine
The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
Nuevo tratamiento para adelgazar: mucho marketing y resultados discretos
Plenity está aprobado por la FDA como un dispositivo que contiene granos de un hidrogel absorbente de origen vegetal. Cada grano se “infla” hasta 100 veces su tamaño, llenando una cuarta parte del estómago de una persona.
New Weight Loss Treatment Is Marked by Heavy Marketing and Modest Results
Approved as a device, not a drug, Plenity contains a plant-based gel that swells to fill 25% of a person’s stomach, to help people eat less. Results vary widely but are modest on average.
A Proposal to Import Drugs from Other Countries Creates an Unusual Alliance in the Senate
As a Senate committee considered legislation to reauthorize the FDA’s user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.
At a Bay Area ‘Test-to-Treat’ Site, Few Takers for Free Antivirals
In carrying out the federal covid-19 “test-to-treat” initiative, California is targeting the uninsured by outfitting 138 testing sites with screenings for free antiviral drugs. But as of mid-June, fewer than 800 people had been prescribed the medicines. And two-thirds of those undergoing screenings are insured.
As Biden Fights Overdoses, Harm Reduction Groups Face Local Opposition
The Biden administration’s latest plan to address opioid overdose deaths includes $30 million for harm reduction measures, but many conservative states don’t allow them.
KHN’s ‘What the Health?’: Taking a Shot at Gun Control
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicare’s trustees board.
Lawmaker Takes on Insurance Companies and Gets Personal About His Health
State Sen. Scott Wiener opens up about a weeklong stint in the hospital last year and what it’s like to live with Crohn’s disease. The San Francisco Democrat is pushing a bill that would require insurance companies to cover certain medications while patients appeal denials.
Misinformation Clouds America’s Most Popular Emergency Contraception
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nation’s most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
Readers and Tweeters Go to the Mat on Abortion Rights and Perceived Wrongs
KHN gives readers a chance to comment on a recent batch of stories.
